New article: RNA medicine enters its second act
Thalia Therapeutics plc has shared a new article titled 'RNA medicine enters its second act' in European Biotechnology Magazine's RNA Therapeutics Special, highlighting the company's strategic focus on RNA therapeutics, including microRNAs, and the potential to address new therapeutic areas like cardiovascular disease and oncology. The article, featuring insights from CEO Dr. David Solomon, underscores the growing momentum and opportunities within the RNA therapeutics market.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA therapeutics, is pleased to share a new article, 'RNA medicine enters its second act', in European Biotechnology Magazine's RNA Therapeutics Special.
The RNA therapeutics market continues to gather momentum, presenting significant opportunities for innovation and value creation. Dr David Solomon, Chief Executive Officer of Thalia Therapeutics, discusses the Company's strategic focus on RNA therapeutics, the potential for new RNA modalities including microRNAs and the opportunity to address new therapeutic areas such as cardiovascular disease and oncology.
Link to the article: https://issuu.com/biocom/docs/ebm_2026_rna_special?fr=sMjMyYTgzNTg2MzQ:
| Thalia Therapeutics plc Dr David H Solomon, Chief Executive Officer | Via Thalia Investor Hub https://investors.thaliatx.com/link/eWdkpr |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke/Josh Ray (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Investor relations and Communications Sarah Hollins Cohesion Bureau Investor relations and Communications Mary-Ann Chang | Tel: +44 (0)20 7183 2463 Tel: +44 (0)7483 284853 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.